← Back to headlines
J&J Lupus Drug Achieves Primary Endpoint in Phase 2 Study
Johnson & Johnson's experimental drug for lupus has successfully met its primary endpoint in a Phase 2 clinical study, marking a positive step in its development.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
